P. Sripongpun (Beau)

Small 👩🏻‍⚕️ in the big 🌏 | Up and running in Hepatology & Gastroenterology

[P. Sripongpun (Beau) @BeauPimMD]

Bumped into these 2 liver legends at #EASLCongress. I’m so lucky 🤩.
A Great Mentor - Great Mentee - and a grand mentee photo ♥️ #EASL2024 #livertwitter

[Nature Reviews Gastroenterology & Hepatology @NatRevGastroHep]

New online! Improving surgical treatments for hepatocellular carcinoma https://t.co/6hXl7nvQqv

[EASL Education @EASLedu]

🌹ACLF or acute decompensation, what’s in a name?
More than words: understanding the distinction could change how we treat and save lives.

📽️Find out more in this #EASLStudio episode on demand
https://t.co/mqp5rDbVk6

@tom_marjot @ProfPaoloAngeli @BavenoCoop @VirginiaHdezGea @RautouE

[P. Sripongpun (Beau) @BeauPimMD]

Thanks @my_ueg for the opportunity to present #GIPSU work at #UEGweek here in Berlin. Our study (Poster MP054) found that Dallas Steatosis Index (DSI) works pretty well in detecting #SLD in Thai individuals with cardiometabolic risk as well. #livertwitter

[JHEP Reports @JHEP_Reports]

🟣Attributable burden of steatotic liver disease on cardiovascular outcomes in Asia

🔓#OpenAccess at 👉https://t.co/AvDfLRm7Sf

#LiverTwitter
#LiverDisease
#SteatoticLiverDisease

[Ramon Bataller @rabataller]

📊 How to interpret PEth blood levels for recent alcohol intake?

Here’s a concise & practical table to guide you.

[Ramon Bataller @rabataller]

🚨 Big milestone in MASLD/MASH!
We now have two FDA-approved drugs:
🔸 Resmetirom (oral, THR-β agonist)
🔹 Semaglutide (weekly SC, GLP-1 RA)

I made this simple side-by-side comparison 👇

[P. Sripongpun (Beau) @BeauPimMD]

Deepest condolences 🙏🏻

[EASLnews @EASLnews]

EASL is deeply saddened to share the news of the passing of Professor Michael P. Manns (1951–2025).

A visionary leader in hepatology, Professor Manns shaped the field through his pioneering research in viral hepatitis, autoimmune liver diseases, transplantation and regenerative medicine. He served as Director of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School for nearly three decades, and held leading roles in Hep-Net, the German Liver Foundation, UEG, and EASL.

His scientific excellence, dedication and mentorship inspired colleagues around the world. Professor Manns received numerous awards, including the EASL Recognition Award (2007) and the UEG Lifetime Achievement Award (2022).

EASL extends heartfelt condolences to his family, friends and colleagues. His legacy will continue to inspire generations of hepatologists.

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

New Review - Recompensation in decompensated cirrhosis

https://t.co/Rwl0K3WTSE

#LiverTwitter #MedTwitter

[NEJM @NEJM]

Original Article: Structured Exercise after Adjuvant Chemotherapy for Colon Cancer (CHALLENGE phase 3 trial) https://t.co/uz69rdc01o

#ASCO25 | @ASCO

[Dina Tiniakos @DinaTiniakos]

After 🔟 years, the new @EASLnews CPG on AutoImmune Hepatitis are here! 👉https://t.co/z7t5Hmgw7o Liver biopsy 🔬 remains a pillar for diagnosis🎯! Congratulations to the author team 🇬🇷 ���🇱🇬🇧 🇩🇰 🇩🇪🇪🇸🇮🇹🇭🇺 &EASL @ESP_Pathology @my_ueg @eemh_hasl @UKLiverPath @LiverPath_HPHS

[NEJM @NEJM]

Original Article: Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (SYMMETRY trial) https://t.co/ETQc0Bk7bv

@EASLnews | #EASLCongress

[Journal of Hepatology @JHepatology]

🆕CPG in press❕

EASL Clinical Practice Guidelines on the management of autoimmune hepatitis

Find it here👉https://t.co/G88THQA0Ph

@EASLnews
@EASLedu

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

Metabolic dysfunction-associated steatotic #liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment https://t.co/uViLbyVfKN
#MASLD #MASH #obesity #T2D #CVD
#OpenAccess

[Elliot Tapper @ebtapper]

Important study in @NEJM
❤️ seeing @NoureddinMD front page!
😁for treatments to reverse #cirrhosis
⚠️careful not to over interpret negative phase 2b with *signals*
🧐everyone should learn about FGF21, a fascinating hormone at the intersection of liver metabolism and fibrogenesis

[Arndt Vogel @ArndtVogel]

Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for HCC
@TheLancet
https://t.co/UasBnOgzWY
🔎CheckMate 9DW
👉mOS 23·7 vs 20·6 mo
👉ORR 36 vs 13%
👉Consistent efficacy in ALBI 1 and 2
🧐Great new option for 1st line HCC
@myESMO @EASLedu @ILCAnews #livertwitter

[NEJM @NEJM]

In patients with compensated cirrhosis from metabolic dysfunction–associated steatohepatitis, efruxifermin did not significantly reduce fibrosis at 36 weeks. Full SYMMETRY trial results: https://t.co/ETQc0Bk7bv

@EASLnews | #EASLCongress

[P. Sripongpun (Beau) @BeauPimMD]

@Apichatka @Yujun__Wong Big hands 👏🏻👏🏻👏🏻 @Yujun__Wong

[P. Sripongpun (Beau) @BeauPimMD]

Screening for SLD in general practice, DSI using routinely available parameters provides an impressive diagnostic accuracy. We’re more than welcome #EASLCongress attendees to visit our poster at FRI-009 Public Health zone. 😊 #GIPSU #livertwitter #EASL2025

[Elliot Tapper @ebtapper]

The greatest review written on liver biopsy: indications, interpretation, and its future

By Dr Purva Gopal and colleagues in @HepCommJournal

Open access https://t.co/llLYkPtpXq

#livertwitter #PathTwitter

[Dr.Bornie @Apichatka]

Please enjoy our #poster #WED-150-YI 📌 💡Biomarkers based on #HCC surveillance are more cost-effective than US + AFP in #Thailand.
#EASLCongress #livertwitter @EASLedu Congratulations to my mentee, Tanat